These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38988823)

  • 1. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.
    Eguren-Santamaría I; Rodríguez I; Herrero-Martin C; Fernández de Piérola E; Azpilikueta A; Sánchez-Gregorio S; Bolaños E; Gomis G; Molero-Glez P; Chacón E; Mínguez JÁ; Chiva S; Diez-Caballero F; de Andrea C; Teijeira Á; Sanmamed MF; Melero I
    Oncoimmunology; 2024; 13(1):2373519. PubMed ID: 38988823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
    Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
    Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BT7480, a novel fully synthetic
    Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
    Rodríguez-Ruiz ME; Rodríguez I; Mayorga L; Labiano T; Barbes B; Etxeberria I; Ponz-Sarvise M; Azpilikueta A; Bolaños E; Sanmamed MF; Berraondo P; Calvo FA; Barcelos-Hoff MH; Perez-Gracia JL; Melero I
    Mol Cancer Ther; 2019 Mar; 18(3):621-631. PubMed ID: 30683810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.
    Wei H; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai M; Hellstrom I; Hellstrom KE; Guo Y
    PLoS One; 2013; 8(12):e84927. PubMed ID: 24367702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M
    Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
    Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
    Front Immunol; 2020; 11():577. PubMed ID: 32391001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
    Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
    Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
    Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
    Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
    Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
    Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.